CLOs on the Move

Western Oncolytics

www.westernoncolytics.com

 
Western Oncolytics is developing a new generation of oncolytic viral immunotherapies to help patients accross the globe beat cancer
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

TEI Biosciences

TEI Biosciences is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Colorado Choice Health Plan

Colorado Choice Health Plan is a Alamosa, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stone Clinical Laboratories

The most innovative, patient and provider focused preventative diagnostic laboratory in the industry

Veracyte

Veracyte is a pioneering genomic diagnostics company. Our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. We ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. We are giving patients a clearer path forward. Through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. Veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today`s clinical practice standards. We are making a difference in the lives of physicians and patients. We are doing something real.

BioClin Therapeutics Inc

BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.